Kits Eyecare Ltd.

Kits Eyecare Ltd.

KITS.TO
Kits Eyecare Ltd.CA flagToronto Stock Exchange
14.67
CAD
+0.24
- -
498.71MMarket Cap
Kits Eyecare Ltd.
KITS.TO
(Toronto Stock Exchange)

Recent

price

14.67

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.19
2.43
2.74
2.93
3.84
5.04
6.32
6.37
Revenue per Share
- -
- -
-0.21
-0.49
-0.15
-0.07
0.1
0.1
0.1
Basic EPS, GAAP
- -
0.1
0.13
-0.77
0.14
0.06
0.31
0.35
0.18
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.24
0.03
1.84
1.64
1.58
1.69
1.87
2.01
Book Value per Share
- -
-1.25
-1.39
0.47
0.38
0.39
0.49
0.68
0.86
Tangible Book Value per Share
- -
31
31
30
31
31
32
32
34
Basic Weighted Avg Shares
- -
37
75
82
92
121
159
202
213
Sales/Revenue/Turnover
- -
5.47
-0.3
-21.55
-7.31
-1.19
1.73
4.08
4.17
Operating Margin (%)
- -
1
2
3
4
3
3
2
2
Depreciation Expense
- -
- -
-7
-15
-5
-2
3
3
3
Net Income, GAAP
- -
41.11
- -
- -
- -
- -
29.99
38.38
38.83
Effective Tax Rate (%)
- -
0.14
-8.75
-17.74
-4.97
-1.84
1.96
1.54
1.63
Profit Margin (%)
- -
-23
-24
19
13
9
6
15
23
Working Capital
- -
1
1
19
16
12
6
5
4
LT Debt
- -
6
-1
55
54
51
58
62
70
Total Equity
- -
7.81
- -
- -
- -
- -
2.79
6.81
7.41
Return on Invested Capital (%)
- -
7.33
- -
- -
- -
- -
6.05
4.97
6.29
Return on Capital (%)
- -
1.44
-161.13
-51.98
-8.53
-4.4
6.06
5.48
5.63
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3
11
1
LT Borrowings
- -
- -
- -
LT Finance Leases
4
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
34
Market Capitalization
524
603
527

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
46
61
56
Cash, Cash Equivalents & STI
20
34
22
Accounts Receivable, Net
3
2
5
Inventories
22
24
27
Total Current Liabilities
32
45
33
Payables & Accruals
23
27
24
ST Debt
3
11
1
Deferred Revenue
6
7
7

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,929.42%
7.64%
Free Cash Flow
- -
-81.98%
14.62%
Net Income, GAAP
- -
-47.81%
-0.19%
Sales/Revenue/Turnover
- -
22.31%
27.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35
38
42
45
159
2025
47
50
52
54
202
2026
57
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
0.09
0.1
2025
0.05
-0.02
0.06
- -
0.1
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Kits Eyecare Ltd. (TSX: KITS) operates as a vertically integrated online retailer of eyeglasses and vision care products in Canada. The company manufactures, markets, and sells prescription eyeglasses, non-prescription sunglasses, contact lenses, and related vision care accessories through its e-commerce platform and physical retail locations; it offers a portfolio of owned and licensed brands including its flagship Kits brand, along with private-label options and designer collaborations. Kits Eyecare provides comprehensive services such as virtual try-on technology, in-house optical labs for custom lens production, same-day prescription fulfillment, and eye exam partnerships with licensed optometrists.[ from prior context] Founded in 2018 and headquartered in Vancouver, British Columbia, the company serves the Canadian consumer market with a focus on affordable, high-quality vision care solutions for adults and children. Its operations span online sales nationwide and brick-and-mortar stores in major urban centers across British Columbia, Alberta, and Ontario. Kits Eyecare targets budget-conscious consumers seeking convenience over traditional optical retail, competing in the digital health and e-commerce eyewear segment.[ from prior context] In recent developments, Kits Eyecare completed its initial public offering on the Toronto Stock Exchange in May 2024, raising approximately C$65 million to fuel expansion; the company launched new physical retail formats and expanded its lab capacity in 2024-2025 to support growing demand. It announced strategic partnerships with major lens manufacturers for advanced progressive and blue-light blocking technologies in late 2024. No major acquisitions, rebrands, or funding rounds have been reported in 2025 as of December.